| External factors: | BI+PAC |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Breast cancer |
| Experiment: | SA-β-gal activity assay |
| Description: | Our results showed that β-galactosidase staining was more prominent in untreated resistant controls in MCF 7/TAM and T-47D/TAM cells. However, on either drug treatments staining of these cells were decreased. Moreover, the numbers of stained cells in BI-PAC treatment are sparsely visible in both cells with respect to other treatments and controls. |
| Target gene: | P38 |
| R-EF-Target gene: | Downregulation |
| Official symbol(s): | P38 |
| Target gene experiment: | Western blot |
| Target gene description: | In specific we also found that the activated p38 levels in BI-PAC treatments were drastically reduced in comparison to either drug. |
| Regulatory pathway: | NF-κB |
| R-EF-Pathway: | Downregulation |
| Official symbol(s): | NFKB1 |
| Pathway experiment: | Western blot |
| Pathway description: | In order to further ratify these results we carried immunoblot studies of downstream molecules of NF kb signaling such as IL6, XIAP, MMP2, MMP9 and cleaved caspase 9. We found that considerable decreased expression of IL6, XIAP, MMP2, and MMP9 were observed in combination treatments in comparison to other individual drug treatments and controls while contrastingly apparent increase of caspase 9 was observed in treatments. |
Annotation: